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THYMOGLOBULIN AS PART OF THE PRE-TRANSPLANT CONDITION- 
ING FOR UNRELATED DONOR STEM-CELL TRANSPLANTATION A 
DOSE-FINDING STUDY 
Remberger, 3/I.p.1; Ri~gd&, O. ~ 1. Cli~ical b~*m~H~ology, Karoli~slea 
b~stit~ttet, Stockholm, Stockholm, Szvede~; 2. C ~ter fi~r Alloge~Mc Stem 
Cell T~:a~spla~ztatio~z, Stockholm, S~edem 
To find the optimal dose of Thymoglobulin as part of the condi- 
tioning, de-escalating doses of Thymoglobulin was given to 169 con- 
secutive stem cell transplantation (SCT) patients with an HLA-com- 
patible unrelated onor. Initially a total dose of 10 mg/kg was used 
(n=67). The total dose was then lowered to 8 mg/kg (n=24), 4 mg/kg 
(n=54) and finally to 6 mg/kg (n=24). Patients were divided into three 
groups: a high dose (10 mg/kg), an intermediate dose (6-8 mg/kg') 
and a low dose group (4 mg/kg). Patient characteristics differed 
between the three groups as follows: the intermediate dose group 
included fewer patients in CR1/CP1, the low dose group had the 
highest median patient age while the high dose group received a
lower nucleated cell-dose. Condit ioning consisted either of 
Bn16/Cy120 or Cyl20/TBI IOGy, and most patients received 
CsA+MTX as GVItD prophylafis. Results. The incidence of acute 
GVHD grades III-IV decreased with increasing dose of Thymoglob- 
ulin. TRM was similar in the high and low dose, while the intermedi- 
ate dos showed a non-significant lower TRM rate. Among patients 
with acute lenkaemia (n=104), the lowest relapse rate and the best 
RFS was seen in the intermediate dose group. Patients with CML 
(n=38) were only divided into a high (>6 mg/kg) and a low dose 
group (>6 mg/kg) due to iow number of patients. In CML patients 
we found a lower relapse incidence and a better RFS in the low dose 
group (17% vs. 48% and 69% vs. 42%). Most patients with a non- 
malignant disease received high dose. Survival among non-naalignant 
diseases was 76%. Conclusion. Optimal dose of Thymoglobulin 
seems to be dependent of diagnose. Patients with acute leukaemia 
might need a higher dose (6-8 mg/kg) than CML patients (4 lng/kg). 
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OUTCOME OF HEMATOPOIETIC PROGENITOR CELLS TRANSPLANT IN 
PATIENTS WITH ACUTE MYELOGENOUS LEUKEMIA IN FIRST COM- 
PLETE REMISSION REPORT FORM A SINGLE INSTITUTION 
MiloJle, G.A.; Marti~zez Rolo~, 57.; Fer~m~dez, I.I.; Co~'vado, C.S.; 
Pavlovsky, S.; ff~mi, M. FUNDALEU, Bue~os Ai~'es, A~'ge~ti~a. 
We analyzed 73 consecutive patients during June 1991 to June 
2002 with acute myelogenous leukemia (AML) who underwent 
hematopoietic progenitor ceils trans- planta tion (PCT) in 1st 
complete remission.Adult pts received induction chemotherapy 
with Citarabine-Mitoxantrone (7/3), I or 2 cycles and a BFM- 
AML regimen in children, all pts received consolidation with 
Citarabine 12 gr/m2 + Mitoxantrone 24 mg/m2 x 1-4 courses fol- 
lowed by G-CSF 5ug/Kg SC daily.The ablative regimens were 
busulfan and cyclophosphalnide (52 pts) and with etoposide (21 
pts).Tbe median age was 35 years old (2-65), and 12 pts(16%) 
were <15 years old; 33(45%) were females. Distribution within 
the FAB classification was as follows: M0:7 pts(10%), Ml :8  
pts(11%), M2:19 pts(26%), M3:3 pts(4%), M4:25 pts(34%), M5:6 
pts (9%), M6:I pts(l%), Biphenotypic:4 pts(5%).The median of 
WBC at diagnosis was 10.0x109/1 (1.0-690.0), only 4 pts had 
>100.000 x 109/1.According to the cytoge- netics studies at time of 
diagnosis, the risk groups were:favorable 5 pts (7%), intermediate 
22 pts(30%), unfavorable 20 pts (28%), not evaluable 9 pts(12%) 
and not done in 17 pts(23%).Two courses of induction were 
needed to achieved CR in I0 pts(14%); 30% received 2 or + 
courses of consolidation therapy before autograft. Sixty two pts 
received peripheral blood progenitor ceils (PBPC) and I lpts 
PBPC + bone marrow.The median time to achieved ANC 
>l.0x109/1 was 12 days (8-54); 80% of the pts recovered >25.0 
x109/1 platelets counts in a median time of 30 days (8-364).Treat- 
ment related mortality (TRM) was 8%(6 pts). Thirty five out of 
73 pts (47%) were alive and in continous complete remission for a 
median of 83 months (1-130).The probabilities of event free sur- 
vival and overall sur viral at 5 years were 47 and 54% respective- 
ly. Younger pts <=50 years old (53 pts) had a better outcome than 
>50 years old (20 pts)(EFS=59% vs 18%, p <0.001; OS=65% vs 
20%, p< 0.001). No statistical differences in event free survival 
and overall survival was observed according to WBC at diagnosis, 
FAB clasification, cytogenetic prognostic group, number of induc- 
tion or consolidation cycles. In summary, our retrospective non 
randomized analysis shows that 47% of selected adult p s with 
AML in I CR can obtain a long-term benefit with high dose 
chemotherapy and autologous PCT. 
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LOW TOXICITY AND EFFICACY OF ns3"SAMARIUM-EDTMP/MELPHA- 
LAN AS A CONDITIONING REGIMEN FOR SECONDARY ACUTE MYEL- 
OGENOUS LEUKEMIA 
Roch'igz~ez, V/; AJ~Mt, C.A/; ErlaJzdsoJ~, L.2; I;Uisemalz, G/; Al~del"so~z, 
P.M.1 1. Depart1*lem of Pediatric and Adolesce*~t MedMlTe, Divisio** of 
Pediatric Hematology 01zcology, M,Uo Cli*~ic a11d Fo~,Tdatiol~, 
Rochester, k/iN; 2. Divisio*~ of He~*mtology, Tra,zspla,zt Ce~zter, 3/ILt3,o 
Cli**ic a~d FoTtnclatiom Rochester, MN; 3. Departmellt of NiMear" Med- 
ici*Te, 3/Iajo Cli,~ic alJd Fom~clatiolz, Rochester, M~ 
With the use of more intensive and effective chemotherapy, radia- 
tion, and the improvement in cancer supportive care, many children 
with malignancies become long-term survivors. Following therapy 
there is a low risk of myelodysplastic s3mdrome and secondary AML 
that are often resistant m conventional therapy including bone mar- 
row transplantation. We report he successful se of a novel prepara- 
tive regimen in a patient with secondary AML. This reoqmen uses 15~- 
Samarium ethylenediaminetetramethylenephosphonate 
(lS>Sm-EDTMP) to provide marrow irradiation with an estimated 
4000 cGy to the red marrow. This salne preparative r gimen has been 
used in multiple myeloma t Mayo Clinic. A 15 year old female devel- 
oped secondary AML 4 years after completion of therapy for metasta- 
tic Ewing's sarcoma (EWS). Patient was treated with combination 
chemotherapy of alternating cycles of vincristine, doxorubicin, 
cyclophosphamidc alternating with ifosfamide and etoposide. Periph- 
eral blood progenitor stem cells were collected after the second cycle 
of chemotherapy with future plans of consolidation with high dose 
chemotherapy and autologous tem cell rescue, however, due to 
patient's excellent response to chemotherapy and surgery, therapy was 
completed without the need of high dose chemotherapy. She received 
a total lung radiation dose of 1200 cGy. Four years following comple- 
tion of therapy for EWS, she developed pancytopenia. Bone marrow 
examination confirmed the diagnosis of AML with monosomy 7. 
Chemotherapy (high dose cytosine arabinoside and L-asparaginase) 
was administered resulting in morphologic and cytogenetic remission. 
No HLA-matched related donor was available for a bone marrow 
transplant. High dose samarium (day -14; dose 30 mCi/kg I~3-Snl- 
EDTMP) and melphalan (day -2; dose 140 rag/m-') were chosen as
conditioning regimen to avoid potential lung complications due to 
previous lung radiation. A total of 6.1 x 10 e8/kg mononuclear cells 
were infused on day 0. Patient achieved engrafinent day +40 (no 
colo W stimulating factors were given). She has excellent performance 
status and no apparent post transplant complications. At 18 months 
post-autologous stem cell transplant, she continues in complete 
remission. I>-Sln-EDTMP and melphalan is a novel, well tolerated 
regimen and worthy of further study in acute leukemia. 
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AUTOLOGUS STEM CELL TRANSPLANTATION AS POSTREMISSION 
THERAPY FOR ACUTE MYELOID LEUKAEMIA 
GmdoTd, A.; Spe~-otto, A.; TomadiTd, U.; Damia1~i, D.; Fa~im R. Divi 
sioTz of He~qatology UMveT"sity Hospital, ~tiJze, Italy. 
Autologus tem cell transplantation can be employed as a postre- 
mission therapy in AML but its role remains controversial. 
Between 1990 and 2001 27 AML pts, without an ItLA-identical 
sibling donor, were autografted at our Division of Hematology 
using unpurged haematopoietic stem cells. Pts were considered as 
having a high-risk (HR) disease if they present at least one of the 
following: secondary AML, unfavourable karyotype, resistant dis- 
ease to first course of CHT. All the others were considered stan- 
dard risk (SR) pts. Hematopoietic stem cells source was bone lnal'- 
row in 25 pts and peripheral blood in 2. At the time of ASCT all 
108 
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pts were in CR. Conditioning regimen:busulfan d cyclophos- 
phamidc. Engraftment was observed in all cases; no TRM was 
recorded. As by august 2002, 16 (59%) pts are alive in continuos 
CR at a median follow-up from transplant of 86 months (range 
10 148) wlnile 11 (41%) relapsed at  median time from transplant 
of 13 months (range 6-21). Of these, 4 (36.5%) are alive in 2CR 
after salvage therapy and 7 (63.5%) died for disease progression. 
The probability of OS and DFS of the whole population were 67 
% and 56% at a median time from transplant of 46 (21-168) and 
21 (6-148) months respectively. There was a statistically signifi- 
cant difference in OS (P 0, 0018) and DFS (P 0, 019) comparing 
HR and SR AML pts in favour of SR group. With the limitation 
of the small pt number, none of the other analyzed factors (sex, 
age, MNC dose, interval between diagnosis and transplantation) 
was found to influence the OS and DFS. Our report confirms that 
ASCT could improve the outcome of SR AML pts while less 
favourable results were obtained in HR AML pts. What clearly 
emerges i the importance of stratifying pts according to prognos 
tic factors in order to employ the appropriate risk-adapted thera- 
peutic approaches. This would suggest hat, pts with HR AML 
and a suitable related or unrelated onor, should be allo-trans- 
planted as soon as possible after the achievement of CR; in such 
HR cases, however, ASCT could be used if no other alternative 
treatments are available. We also think that for older IIR pts or 
for HR AML pts without a donor, investigational pproaches 
(antibody-targeted herapy, other new drugs, leukaemia vaccines, 
reduced-intensity conditioning regimens, aploidentical allogeneic 
transplant) should be strongly pursued. 
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